Virological rebound and its consequences during treatment interruption

Current Opinion in HIV and AIDS

Volumn 2, Issue 1, 2007, Pages 1-5

  Van Lunzen, Jan ^a   Hoffmann, Christian ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Institute for Interdisciplinary Medicine   (Germany)

Author keywords

AIDS; Antiretroviral therapy; HIV; Treatment interruption; Virological rebound

Indexed keywords

EMTRICITABINE; LAMIVUDINE; TENOFOVIR;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELL COUNT; COMORBIDITY; DISEASE MARKER; HEALTH CARE; HELPER CELL; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; KIDNEY FAILURE; KINETICS; PRIORITY JOURNAL; PROTEIN METABOLISM; REVIEW; TREATMENT OUTCOME; VIREMIA; VIRUS TRANSMISSION;

EID: 34250644960     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328011aab1     Document Type: Review

References (55)

1. Davey RT Jr, Bhat N, Yoder C, et al. HIV-1 and T cell dynamics after interruption of HAART in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A 1999; 96:15109-15114.
2. Garcia F, Plana M, Vidal C, et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 1999; 13:F79-F86.
3. Hatano H, Vogel S, Yoder C, et al. Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression. AIDS 2000; 14:1357-1363.
4. Burton CT, Nelson MR, Hay P, et al. Immunological and virological consequences of patient-directed antiretroviral therapy interruption during chronic HIV-1 infection. Clin Exp Immunol 2005; 142:354-361.
5. Gisslen M, Rosengren L, Hagberg L, et al. Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in HIV-1 infection. AIDS Res Ther 2005; 2:6. Small but elegant study indicating subclinical damage of the CNS during treatment interruption.
6. De Jong MD, de Boer RJ, de Wolf F, et al. Transient overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment: role of target cell availability. AIDS 1997; 11:F79-F84.
7. Birk M, Svedhem V, Sonnerborg A. Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy. AIDS 2001; 15:1359-1368.
8. Chun TW, Davey RT Jr, Ostrowski M, et al. Relationship between preexisting viral reservoirs and the re-emergence of plasma viremia after discontinuation of HAART. Nat Med 2000; 6:757-761.
9. Ho DD, Zhang L. HIV-1 rebound after antiretroviral therapy. Nat Med 2000; 6:736-737.
10. Imamichi H, Crandall KA, Natarajan V, et al. HIV type 1 quasi species that rebound after discontinuation of HAART are similar to the viral quasi species present before initiation of therapy. J Infect Dis 2001; 183:36-50.
11. Fagard C, Oxenius A, Gunthard H, et al. A prospective trial of structured treatment interruptions in HIV infection. Arch Intern Med 2003; 163:1220-1226.
12. Bedimo R, Chen RY, Westfall AO, et al. Sustained HIV viral suppression following treatment interruption: an observational study. AIDS Res Hum Retroviruses 2006; 22:40-44.
13. Goulder PJR, Brander C, Tang Y, et al. Evolution and transmission of stable CTL mutations in HIV infection. Nature 2001; 412:334-338.
14. Fagard C, Bandelier CY, Ananworanich J, et al. Biphasic decline of CD4 cell count during scheduled treatment interruptions. AIDS 2005; 19:439-441. This study is important in terms of the biphasic CD4 kinetics during prolonged treatment interruptions.
15. Wit FW, Blanckenberg DH, Brinkman K, et al. Safety of long-term interruption of successful antiretroviral therapy: the ATHENA cohort study. AIDS 2005; 19:345-348.
16. Maggiolo F, Ripamonti D, Gregis G, Quinzan G, et al. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial. AIDS 2004; 18:439-446.
17. Pellegrin I, Thiebaut R, Blanco P, et al. Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and >400 CD4+ cells/microl? Impact on immunovirological parameters. J Med Virol 2005; 77:164-172.
18. 3. J Infect Dis 2005; 192:1787-1793.
19. Mata RC, Viciana P, de Alarcon A, et al. Discontinuation of antiretroviral therapy in patients with chronic HIV infection: clinical, virologic, and immunologic consequences. AIDS Patient Care STDS 2005; 19:550-562.
20. Touloumi G, Pantazis N, Antoniou A, et al. Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences. J Acquir Immune Defic Syndr 2006; 42:554-561. This large European collaboration identifies characteristics of subjects with the greatest risk for CD4 T-cell loss during treatment interruption.
21. Tebas P, Henry K, Mondy K, et al. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in HIV-infected patients: implications for intermittent therapeutic strategies. J Infect Dis 2002; 186:851-854.
22. Molina-Pinelo S, Vivancos J, De Felipe B, et al. Thymic volume predicts CD4 T-cell decline in HIV-infected adults under prolonged treatment interruption. J Acquir Immune Defic Syndr 2006; 42:203-206. Small study demonstrating that thymic volume predicts CD4 T-cell loss during treatment interruption.
23. Levy Y, Durier C, Lascaux AS, et al. Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals. AIDS 2006; 20:405-413. In this pilot study the concept of using therapeutic vaccination to improve viral control after treatment interruption has been tested with some success.
24. Jacobson JM, Pat Bucy R, Spritzler J, et al. Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the Results of AIDS Clinical Trials Group 5068. J Infect Dis 2006; 194:623-632.
25. Trkola A, Kuster H, Rusert P, et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005; 11:615-622. This is the first in-vivo study describing the positive effect of neutralizing anti-HIV antibodies on plasma viremia and viral rebound kinetics when infused during treatment interruption. Larger studies to prove these findings are under way.
26. Foli A, Maserati R, Barasolo G, et al. Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions. Antivir Ther 2004; 9:123-132.
27. Garcia F, Plana M, Arnedo M, et al. Effect of mycophenolate mofetil on immune response and plasma and lymphatic tissue viral load during and after interruption of highly active antiretroviral therapy for patients with chronic HIV infection: a randomized pilot study. J AIDS 2004; 36:823-830.
28. Henry K, Katzenstein D, Cherng DW, et al. A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102. J Acquir Immune Defic Syndr 2006; 42:140-148. Interesting concept study that aims to keep the CD4 count up during treatment interruption by the application of adjuvant interleukin-2. The clinical significance of this approach, however, remains to be proven.
29. Keh CE, Shen JM, Hahn B, et al. Interruption of antiretroviral therapy blunts but does not abrogate CD4 T-cell responses to interleukin-2 administration in HIV infected patients. AIDS 2006; 20:361-369.
30. Wolf E, Hoffmann C, Procaccianti M, et al. Long-term consequences of treatment interruptions in chronically HIV-1-infected patients. Eur J Med Res 2005; 10:56-62.
31. Scriba TJ, Zhang HT, Brown HL, et al. HIV-1-specific CD4+ T lymphocyte turnover and activation increase upon viral rebound. J Clin Invest 2005; 115:443-450.
32. Altfeld M, van Lunzen J, Frahm N, et al. Expansion of preexisting, lymph node-localized CD8+ T cell during supervised treatment interruptions in chronic HIV-1 infection. J Clin Invest 2002; 109:837-843.
33. Hess C, Altfeld M, Thomas S, et al. Full maturation of HIV-specific CD8 T cells is associated with control of viral replication. Lancet 2004; 363:863-866.
34. Boschi A, Tinelli C, Ortolani P, Arlotti M. Safety and factors predicting the duration of first and second treatment interruptions guided by CD4+ cell counts in patients with chronic HIV infection. J Antimicrob Chemother 2006; 57:520-526.
35. Skiest DJ, Morrow P, Allen B, et al. It is safe to stop antiretroviral therapy in patients with preantiretroviral CD4 cell counts >250 cells/microL. J AIDS 2004; 37:1351-1357.
36. 6 cells/l. AIDS 2005; 19:287-294.
37. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344:472-480.
38. Lawrence J, Mayers DL, Hullsiek KH, et al. Structured treatment interruption in patients with multidrug-resistant HIV. N Engl J Med 2003; 349:837-846.
39. Hakim J, on behalf of the DART Trial Team. A structured treatment interruption (STI) strategy of 12 week cycles on and off ART is clinically inferior to continuous treatment in patients with low CD4 counts before ART: a randomisation within the DART Trial. In: Program and abstracts of the XVI International AIDS Conference; 13-18 August 2006; Toronto, Canada. Abstract THLB0207.
40. Ruiz L, Romeu J, Martinez-Picado J, et al. Selection of drug-resistance mutations in chronic HIV-infected patients during therapy interruptions guided by CD4+ T-cell counts and viral load levels: the TIBET study. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; 2005; Boston, MA, USA. Abstract 679.
41. El-Sadr W, Neaton J. Episodic CD4 guided use of antiretroviral therapy is inferior to continuous therapy: results of the SMART study. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; 2006; Denver, CO, USA. Abstract 106LB.
42. El-Sadr W, for the SMART Study Group. Inferior clinical outcomes with episodic CD4-guided antiretroviral therapy aimed at drug conservation (DC) in SMART study: consistency of finding in all patient subgroups. In: Program and abstracts of the XVI International AIDS Conference; 13-18 August 2006; Toronto, Canada. Abstract WEAB0203.
43. Lundgren JD, for the SMART Study Group. Progression of HIV-related disease or death (POD) in the randomised SMART Study: why was the risk of POD greater in the CD4-guided ((re)-initiate ART at CD4<250 cells/μL) drug conservation (DC) vs the virological suppression (VS) arm? In: Program and abstracts of the XVI International AIDS Conference; 13-18 August 2006; Toronto, Canada. Abstract WEAB0203.
44. Danel C, Moh R, Minga A, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in West Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 2006; 367:1981-1989. A well designed randomized trial on 326 patients in Cote d'Ivoire showing that treatment interruption may lead to 2.5-fold higher morbidity rates in this population, mainly due to severe bacterial infections. The findings, however, may not be extrapolated to other settings.
45. Ananworanich J, Gayet-Ageron A, Le Braz M, et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet 2006; 368:459-465. Important study on 430 patients with relative preserved immunocompetence, indicating that scheduled treatment interruption is safe and may lead to substantial drug savings. Somewhat conflicting results compared with [41].
46. 3. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; 2006; Denver, CO. Abstract 101.
47. Goicoechea M, Haubrich R. CD4 lymphoctye percentage versus absolute CD4 lymphocyte count in predicting HIV disease progression: an old debate revisited. J Infect Dis 2005; 192:945-947.
48. 3. J Infect Dis 2005; 192:950-957.
49. Colven R, Harrington RD, Spach DH, et al. Retroviral rebound syndrome after cessation of suppressive ART in three patients with chronic HIV infection. Ann Intern Med 2000; 133:430-434.
50. Kilby JM, Goepfert PA, Miller AP, et al. Recurrence of the acute HIV syndrome after interruption of ART in a patient with chronic HIV infection: a case report. Ann Intern Med 2000; 133:435-438.
51. Knysz B, Gasiorowski J, Czarnecki M, Gladysz A. Viral rebound syndrome in two HIV-1-positive patients after structured treatment interruption. Viral Immunol 2005; 18:579-581.
52. Ananworanich J, Phanuphak N, Nuesch R, et al. Recurring thrombocytopenia associated with structured treatment interruption in patients with HIV infection. Clin Infect Dis 2003; 37:723-725.
53. Sellier P, Clevenbergh P, Mazeron MC, et al. Fatal interruption of a 3TC-containing regimen in a HIV-infected patient due to re-activation of chronic hepatitis B virus infection. Scand J Infect Dis 2004; 36:533-535.
54. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of HIV type 1. N Engl J Med 2000; 342:921-929.
55. Tovanabutra S, Robison V, Wongtrakul J, et al. Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr 2002; 29:275-283.